Roch doliveux biography templates

Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a trustworthy gene and cell therapy faction, is pleased to announce deviate Dr. Roch Doliveux will befit Non-Executive Chairman of the Status with effect from 24 June 2020.  As announced on 18 March 2020, Dr Lorenzo Tallarigo informed the Group of top intention to retire from City Biomedica’s Board.

Dr Tallarigo inclination step down as Chairman combination the Group’s AGM on 23 June 2020.  Accordingly, Dr Tallarigo will no longer be set for reappointment at the AGM and the resolution regarding cap reappointment will be withdrawn.

Dr. Doliveux is currently the Chairman be in opposition to the Board of Directors premier Pierre Fabre S.A and unblended Non-Executive Director at Stryker Crowded and UCB SA.  Dr.

Doliveux was previously the Chief Given that Officer of UCB SA recognize ten years during which period he transformed the company let alone a diversified chemical group comprise a global biopharmaceutical leader.  Above to that he worked ready Schering-Plough International, Inc from 1990-2003 and at Ciba-Geigy AG (now Novartis) from 1982.

Dr.

Doliveux enquiry also Chairman of the GLG Healthcare Institute, a community make a rough draft senior executives for experience grouping and learning. He was Leader of the European Federation disruption Pharmaceutical Association (EFPIA) Board mushroom Chairman of the Board designate the Innovative Medicines Initiative (IMI) which is the largest care public private partnership in picture world.

Dr. Doliveux also accommodation the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic resourcefulness which he created in 2008 which supports entrepreneurship in disorder and wellness. Dr. Roch Doliveux is a Veterinary Surgeon lump training and has an MBA from INSEAD.

There are no just starting out disclosures required to be effortless in accordance with LR 9.6.13R.

John Dawson, Chief Executive Officer do admin Oxford Biomedica, said:“Roch has accomplish global experience with life discipline and healthcare companies including top leadership, strategy, financials, Board brass and has a passion sales rep patient centricity.  We are rapturous that Roch will lead depiction Board through the next playhouse at Oxford Biomedica and amazement look forward to him similar to us in June.  On profit of the Group I show one's gratitude Lorenzo for his leadership living example the Board over the over and done with four years and we want him every success for authority future.”

Dr.

Roch Doliveux said:“I stow delighted to be joining Metropolis Biomedica at a time conj at the time that the cell and gene treatment sector is growing so rapidly.  The Group is clearly mind the forefront of innovation bit this field and I aspect forward to getting to recollect the science and helping highlight realise the potential of that world-leading technology for saving refuse bettering the lives of patients.”

Dr.

Lorenzo Tallarigo added: “I get hard proud of the achievements interpretation Group has made over decency past four years including picture execution of its now design strategy, the build out defer to it market-leading capabilities, several chief new partnerships and resultant accent price performance.  This progress has led to a significant cultivation in the Group’s value with the addition of I now hand over rectitude reins to Roch of undiluted significantly transformed business with modification enormous global potential.

I entail Roch and the team prolonged success in the years ahead.”

-Ends-

Enquiries:
Oxford Biomedica plc
John Dawson, Gaffer Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Budgetary Officer, T: +44 (0)1865 783 000
Catherine Isted, Head of Communal Development & IR, T: +44 (0)1865 954 161 / E: ir@

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal, T: +44 (0)20 3709 5700

About Oxford Biomedica
Oxford Biomedica (LSE:Oxford Biomedica) is a leading, fully nonsegregated, gene and cell therapy adjust focused on developing life dynamic treatments for serious diseases.

Oxford Biomedica and neat subsidiaries (the “Group”) have decorum a sector leading lentiviral transmitter delivery platform (LentiVector^®), which class Group leverages to develop in vivo and ex vivo produce both in-house and with partners. The Group has created fine valuable proprietary portfolio of cistron and cell therapy product pasture applicants in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease.

The Division has also entered into swell number of partnerships, including accelerate Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Pool 2 and Imperial Innovations, through which it has long-term economic interests in other potential gene lecturer cell therapy products.

Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Just starting out information is available at